Ernexa Therapeutics Inc. (ERNA)

Every figure this model derived for ERNA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2024-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 37,000 PaymentsToAcquirePropertyPlantAndEquipment 2025-12-31
cash 5,028,000 CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents 2026-06-30
current assets 5,894,000 AssetsCurrent 2026-06-30
current liabilities 2,932,000 LiabilitiesCurrent 2026-06-30
equity 3,200,000 StockholdersEquity 2026-06-30
interest expense 22,000 InterestExpenseDebt 2025-12-31
revenue 582,000 Revenues 2024-12-31
sbc 0 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up ERNA on one particular measure came for.

RatioValue
current ratio2.01
current ratio reported2.01
dilution pct594.0
growth cv2.78
revenue growth755.88
revenue growth per share23.33
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about ERNA's figures. Written by the derivation as it ran, not added afterwards.